CD274 and neoplasm: A global study (KEYNOTE-042, NCT02220894) compared first-line monotherapy with pembrolizumab (a representative of ICIs) with platinum-based chemotherapy in patients with locally advanced/metastatic NSCLC without epidermal growth factor receptor/anaplastic lymphoma kinase alterations and programmed death-ligand 1 (PD-L1) tumor proportion score of ≥ 1%.